Osteosarcoma (OS) is a highly aggressive bone tumor that predominantly affects teenagers and young adults, characterized by rapid growth and a high propensity for metastasis.1 Despite significant advancements in surgical techniques and chemotherapy, the survival rate for OS patients has plateaued over the past decades.2 Understanding the molecular mechanisms underlying OS progression and identifying new therapeutic targets remain critical for improving patient outcomes. Long non-coding RNAs (lncRNAs) are a class of functional RNA molecules that are typically over 200 nucleotides in length and cannot code for proteins.3 Initially considered as “junk DNA”, recent studies have revealed the crucial roles lncRNAs play in a wide range of biological processes, including cellular differentiation, apoptosis, inflammation, and cancer.4